US 12,329,794 B2
Recombinant herpes simplex virus for cancer immunotherapy
Bin He, Chicago, IL (US); and Xing Liu, Chicago, IL (US)
Assigned to The Board of Trustees of the University of Illinois, Urbana, IL (US)
Appl. No. 17/054,338
Filed by THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
PCT Filed Jun. 7, 2019, PCT No. PCT/US2019/035922
§ 371(c)(1), (2) Date Nov. 10, 2020,
PCT Pub. No. WO2019/236931, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/682,202, filed on Jun. 8, 2018.
Prior Publication US 2021/0138009 A1, May 13, 2021
Int. Cl. A61K 35/763 (2015.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C12N 7/00 (2006.01); C12N 15/09 (2006.01); C12N 15/63 (2006.01)
CPC A61K 35/763 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01); C12N 7/00 (2013.01); C12N 15/09 (2013.01); C12N 15/63 (2013.01); C12N 2710/16621 (2013.01); C12N 2710/16632 (2013.01)] 8 Claims
 
1. A method for treating a subject with breast cancer comprising administering to the subject a therapeutically effective amount of a recombinant Herpes Simplex Virus-1 (HSV-1) that expresses only a γ134.5 protein consisting of SEQ ID NO:2 with no wild-type or intact γ134.5 protein expression thereby treating the subject's breast cancer.